861106-90-3

Basic information

• Product Name: 2-bromo-6-nitrobenzyl acetate
• Synonyms: 2-bromo-6-nitrobenzyl acetate
• CAS NO: 861106-90-3
• Molecular Weight: 274.071
• Mol File: 861106-90-3.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 2-bromo-6-nitrobenzyl acetate(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-6-nitrobenzyl acetate(861106-90-3)
• EPA Substance Registry System: 2-bromo-6-nitrobenzyl acetate(861106-90-3)

Safety Data

• Hazardous Substances Data: 861106-90-3(Hazardous Substances Data)

Upstream product

• 58579-54-7 3-bromo-2-(bromomethyl)-1-nitrobenzene 
• 603-83-8 3-nitro-o-tolylamine 
• 55289-35-5 2-bromo-6-nitrotoluene 
• 127-09-3 sodium acetate 
• 127-08-2 potassium acetate 

Downstream Products

• 1285533-08-5 4-aminobenzo[c][1,2]oxaborol-1(3H)-ol 
• 1285533-34-7 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-nitrobenzyl acetate 
• 861106-92-5 (2-amino-6-bromophenyl)methanol 
• 1347720-73-3 C₂₁H₂₄BrN₃O₅ 
• 1374764-25-6 C₁₈H₁₆BrN₃O₃ 
• 1147531-02-9 ((2-bromo-6-nitrobenzyl)oxy)(tert-butyl)dimethylsilane 
• 1361941-08-3 methyl 3-((3-bromo-2-((tert-butyldimethylsilyloxy)methyl)-phenylamino)methyl)-5-tert-butylthiophene-2-carboxylate 
• 1361941-09-4 3-((3-Bromo-2-(hydroxymethyl)phenylamino)methyl)-5-tert-butylthiophene-2-carboxylic acid 
• 1361941-10-7 5-(3-bromo-2-(hydroxymethyl)phenyl)-2-tert-butyl-4H-thieno[3,2-c]pyrrol-6(5H)-one 
• 1361941-11-8 2-bromo-6-(2-tert-butyl-6-oxo-4H-thieno[3,2-c]pyrrol-5(6H)-yl)benzyl acetate 
• 1622303-33-6 N-(3-bromo-2-(((tert-butyldimethylsilyl)oxy)methyl)phenyl)-4-(1-methylcyclopropyl)benzamide 
• 1198765-14-8 N-(3-bromo-2-(((tert-butyldimethylsilyl)oxy)methyl)phenyl)-4-cyclopropyl-2-methylbenzamide 
• 1147531-08-5 N-(2-(((tert-butyldimethylsilyl)oxy)methyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-4-(dimethylamino)benzamide 
• 1622303-14-3 N-(3-bromo-2-(((tert-butyldimethylsilyl)oxy)methyl)phenyl)-4-(dimethylamino)benzamide 

Relevant articles and documents

Novel Bruton's tyrosine kinase inhibitor as well as preparation method and application thereof

The invention relates to a reversible novel Bruton's tyrosine kinase inhibitor which comprises a compound of a formula (I) as shown in the specification, and a stereisomer, a aquo-complex, a solvent compound, a pharmaceutically acceptable salt, an eutectic crystal or a predrug of the compound. The invention further relates to a preparation method of the compound and a method and the application ofthe novel compound in inhibiting BTK (Bruton's Tyrosine Kinase) kinase activity and mutant BTK kinase activity.

FUSED QUINAZOLINE DERIVATIVES AND USES THEREOF

Fused quinazoline derivatives and uses thereof as protein tyrosine kinase inhibitors and aurora kinase inhibitors are disclosed. Said protein tyrosine kinase inhibitors and aurora kinase inhibitors can be used in treating cancers, leukaemia and the diseases relevant to differentiation and proliferation. Said protein tyrosine kinase and aurora kinase dual inhibitors are the compounds represented by the following general formula or salts thereof.

Synthesis and SAR of acyclic HCV NS3 protease inhibitors with novel P4-benzoxaborole moieties

We have synthesized and evaluated a new series of acyclic P4-benzoxaborole-based HCV NS3 protease inhibitors. Structure-activity relationships were investigated, leading to the identification of compounds 5g and 17 with low nanomolar potency in the enzymatic and cell-based replicon assay. The linker-truncated compound 5j was found to exhibit improved absorption and oral bioavailability in rats, suggesting that further reduction of molecular weight and polar surface area could result in improved drug-like properties of this novel series.